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ABSTRACT
Human cytomegalovirus (HCMV) infection is the most frequent infectious complication after conventional
allogeneic stem cell transplantation (alloSCT). From December 1998 to December 2002, we prospectively
monitored HCMV reactivation in 59 patients affected by solid tumors and undergoing nonmyeloablative
alloSCT (NST). Patients were allografted from HLA-identical sibling donors after fludarabine/cyclophosph-
amide-based conditioning regimens. Seventeen (28.8%) of 59 patients presented with HCMV antigenemia, and
14 received ganciclovir, with successful HCMV clearance in all cases. No patient developed HCMV viremia or
disease. The median time to HCMV reactivation was 54 days (range, 16-245 days) after NST. These patients
were compared with a cohort of hematologic patients who were treated with conventional myeloablative
alloSCT. Matching criteria included HCMV risk group, stem cell source, donor type, and age. In the
myeloablative group, HCMV active infection was observed in 47 (85.4%) of 55 patients at a median time of 30
days (range, 13-64 days) after alloSCT, and HCMV infection occurred more frequently (P < .001) and earlier
(P  .001) than in NST patients. Patients affected with solid tumors undergoing NST had a reduced and
delayed incidence of HCMV active infection.
© 2005 American Society for Blood and Marrow Transplantation
KEY WORDS
Human cytomegalovirus infection ● Nonmyeloablative allogeneic stem cell transplantation ● Re-
fractory solid tumor
p
m
e
r
m
t
cNTRODUCTION
Whereas the potential antitumor effect mediated
y donor lymphocytes has been established in many
ematologic malignancies, [1] its efﬁcacy in inducing
linically meaningful responses in solid tumors has
een largely unexplored, despite evidence of its po-
ential beneﬁt in experimental animal models. [2-4]
nly in recent years has the investigational applica-ion of nonmyeloablative allogeneic stem cell trans- a
B&MTlantation (NST) in patients with refractory nonhe-
atologic cancers proved that a graft-versus-tumor
ffect can be generated in patients with metastatic
enal cell cancer and possibly other solid tumors. [5-8]
Nonmyeloablative regimens have a lower treat-
ent-related mortality than conventional myeloabla-
ive allogeneic regimens. [9] However, infectious
omplications remain a consistent cause of morbidity
nd mortality, and human cytomegalovirus (HCMV)
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4s the most common viral infection in the early post-
ransplantation period. [10] To evaluate the incidence
nd outcome of viral infections, we prospectively
onitored active HCMV infection in 59 patients af-
ected by refractory solid tumors and receiving NST
n our institutions, and we compared these results with
hose of 55 matched hematologic patients treated with
onventional myeloablative allogeneic stem cell trans-
lantation (alloSCT).
ATIENTS AND METHODS
atients
From December 1998 to December 2002, 59 con-
ecutive patients, with a minimum follow-up of 100 days,
nderwent NST from an HLA-identical sibling at Isti-
uto Scientiﬁco HS Raffaele and Ospedale Niguarda Ca’
randa, both in Milan, or at Fondazione Maugeri in
avia (all in Italy). These 3 institutions share a phase II
linical trial of NST in refractory solid tumors and fol-
owed a similar surveillance and prevention protocol for
nfections.
To compare the rate of HCMV infection of these
atients with that of patients treated with conven-
ional alloSCT, we analyzed the incidence of HCMV
nfection in a comparable cohort of patients affected
y hematologic malignancies treated and monitored
or HCMV infection during the same time period
December 1998 through December 2002). Fifty-ﬁve
atients who met the criteria for HCMV risk group,
tem cell source, donor type (HLA-identical sibling),
ge, and duration of follow-up were identiﬁed among
2 consecutive patients and were analyzed for HCMV
nfection. Patient characteristics relevant to the study
re reported in Table 1.
onditioning Regimen, Hematopoietic
ell Transplantation, and
osttransplantation Immunosuppression
In 34 patients, the NST conditioning regimen
onsisted of intravenous thiotepa 5 to 10 mg/kg body
eight on day 6, cyclophosphamide 30 mg/kg/d on
ay 4 and day 3, and ﬂudarabine 30 mg/m2/d on
ay 4 to day 3 before transplantation. Twenty-ﬁve
ubjects received cyclophosphamide 30 mg/kg/d on
ay 5 and day 4 and ﬂudarabine 30 mg/m2/d daily
rom day 5 to day 2 before transplantation.
Granulocyte colony-stimulating factor–mobilized
eripheral blood stem cells were transplanted without
urther manipulation on day 0. Patients received a
edian of 4.88  106 CD34 hematopoietic cells per
ilogram (range, 1.5-14) and 2.2  108 CD3 T cells
er kilogram (range, 0.8-3.9). From day 7 until neu-
rophil recovery, granulocyte colony-stimulating fac-
or was administered at 5 g/kg/d. The transfusion
equirement was reported in 25 (42%) of 59 patients.
24Cyclosporin A (Cs-A), used to prevent both graft
ejection and graft-versus-host disease (GVHD), was
tarted 7 days before hematopoietic cell transplanta-
ion (HCT) as an intravenous infusion at 3 mg/kg/d.
ubsequently, patients received Cs-A orally at 6 mg/
g/d in 2 single doses. Methotrexate was adminis-
rated as part of GVHD prophylaxis at 10 mg/m2
ntravenously on day 1 and 8 mg/m2 on days 3 and 6
fter HCT. After transplantation, Cs-A was decreased
y 25% every week starting from day 70 or 90
depending on disease status) and was discontinued if
evere GVHD had not developed.
able 1. Characteristics of Patients
Variable NST AlloSCT
o. of patients 59 55
ex (female/male) 34/25 (57/43) 22/33 (40/60)
edian age at
transplantation, y (range) 42 (17-62) 44 (18-55)
LA-identical sibling
donors 59 (100) 55 (100)
olid tumors
RCC 23 (39) NA
MBC 14 (24) NA
OC 7 (12) NA
Sarcoma 7 (12) NA
Melanoma 2 (3) NA
Others 6 (10) NA
ematologic disease
ALL NA 8 (15)
AML NA 19 (35)
CML NA 18 (32)
MM NA 5 (9)
MDS NA 2 (4)
Others NA 3 (5)
rior CT 42 (71) 30 (54)
rior ASCT 17 (29) 2 (3.6)
CMV risk group
Low (D/R) 2 (3) 3 (5)
Intermediate (D/R) 1 (2) 5 (9)
High (D/R; D/R) 56 (95) 47 (86)
ST conditioning
Flu/Cy 25 (42) NA
Flu/Cy/TT 34 (58) NA
lloSCT conditioning
Bu/Cy NA 30 (55)
Bu/Mel NA 4 (7)
TBI/Cy NA 14 (25)
Others NA 7 (13)
BC/Plt transfusion 25/59 (42) 55/55 (100)
edian overall survival, d
(range) 330 (21-1377) 910 (50-2350)
onrelapse mortality
(at 1 y) 10 (17) 10 (18)
CC indicates renal cell carcinoma; MBC, metastatic breast cancer;
OC, ovarian cancer; ALL, acute lymphoblastic leukemia; AML,
acute myeloid leukemia; CML, chronic myeloid leukemia; MM,
multiple myeloma; MDS, myelodysplastic syndrome; CT, che-
motherapy; ASCT, autologous stem cell transplantation; Flu/
Cy, ﬂudarabine/cyclophosphamide; TT, thiotepa; Bu, busulfan;
Mel, melphalan; TBI, total body irradiation; RBC, red blood
cell; Plt, platelet; NA, not applicable; D, donor; R, recipient.
ata are No. patients (%) unless otherwise noted.In patients with disease progression at day 30 or

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Reduced and Delayed HCMV Infection after Allogeneic NST in Refractory Solid Tumors
B60, but not before day 45, after transplantation,
s-A was withheld without tapering. Tapering sched-
les were modiﬁed at the discretion of the attending
hysician if active GVHD was present.
Patients who underwent conventional alloSCT re-
eived different types of conditioning regimens, most
ommonly cyclophosphamide (60 mg/kg/d for 2 con-
ecutive days) followed by busulfan (4 mg/kg/d for 4
onsecutive days) or by total body irradiation (TBI;
2 Gy). All patients received red blood cell and/or
latelet support. No patient received antilymphocyte
ntibody. GVHD prophylaxis was the same as re-
orted for NST patients.
nti-infectious Prophylaxis: Supportive Care
For both NST and alloSCT, antimicrobial ther-
py followed institutional protocols that consisted of
traconazole or ﬂuconazole for antifungal prophylaxis
nd ciproﬂoxacin for antibacterial prophylaxis. Acy-
lovir was administered at 800 mg/m2 every 8 hours
ntil 90 days after transplantation. No ganciclovir
rophylaxis was administered in either group. The
CMV serologic status was determined before trans-
lantation in all patients and their donors. Platelet
ransfusions were given on a prophylactic basis when
he platelet count was10 109/L or in the presence
f bleeding episodes, whereas red blood cell units
ere transfused in patients with hemoglobin8 g/dL.
ll blood products were ﬁltered and irradiated before
ransfusion.
irologic Follow-up and Preemptive
CMV Therapy
In both NST and alloSCT patients, monitoring
f HCMV infection by antigenemia and viremia de-
ermination started when patients reached a leukocyte
ount of 0.5  109/L. Ethylenediaminetetraacetic
cid–anticoagulated blood samples were collected
eekly until day 100 in all patients and monthly
hereafter until 1 year after transplantation in 48% of
ST patients and in 72% of alloSCT patients. Anti-
enemia was quantiﬁed under a ﬂuorescence micro-
cope by counting the number of pp65-positive pe-
ipheral blood leukocytes/2  105 peripheral blood
eukocytes (PBLs) examined on cytospin preparations
tained with a pool of 3 pp65-speciﬁc monoclonal
ntibodies, according to a previously reported [11] and
ecently standardized [12] procedure. Viremia was
uantiﬁed by inoculating 2  105 PBLs onto human
mbryonic lung ﬁbroblast cell cultures by the shell vial
echnique and then, 16 to 24 hours after inoculation,
y counting the number of ﬁbroblast nuclei positive
or the HCMV immediate-early antigen p72. [13]
During the ﬁrst 100 days after transplantation, all
atients (from both the NST and the alloSCT group)
ith HCMV antigenemia at any level, conﬁrmed at 2 t
B&MTonsecutive controls, or with HCMV viremia received
anciclovir therapy (5 mg/kg intravenously twice
aily) until 2 consecutive negative controls. After day
100, preemptive therapy was given in the presence
f at least 4 positive cells per 2  105 PBLs per slide
r HCMV viremia.
efinitions
HCMV active infection was deﬁned as HCMV
resence in the blood, as shown by positive antigen-
mia conﬁrmed on 2 consecutive tests, in the absence
f clinical manifestations or organ function abnormal-
ties. Self-limiting infection was deﬁned in case of
ntigenemia positive on the ﬁrst test and not con-
rmed at the subsequent control. HCMV infection
as deﬁned as early if it occurred within 100 days after
ransplantation or late when it occurred thereafter.
iagnosis of HCMV disease required documentation
f HCMV infection in tissue samples by virus isola-
ion, histopathology, or immunohistochemistry, along
ith organ function abnormalities. [14]
The HCMV risk groups were deﬁned on the basis
f previous results from myeloablative transplanta-
ions: [15] low risk (donor and recipient serologically
egative), intermediate risk (donor serologically pos-
tive and recipient negative), and high risk (recipient
ositive and donor either negative or positive). The
ay of onset of active infection was deﬁned as the day
hen the diagnostic test was found positive or (if
pplicable) on the basis of signs and symptoms of
rgan involvement. Diagnosis and clinical grading of
cute and chronic GVHD were performed according
o established criteria. [16]
tatistical Analysis
Cumulative incidence curves were produced for
CMV infection up to 365 days after transplantation;
omparison between the 2 curves was made with use
f the log-rank test. Failures from other causes (death)
ere classiﬁed as censored cases. Differences between
ime to HCMV infection and duration of treatment
ere determined by the Mann-Whitney U test. Uni-
ariate and multivariate logistic regression models
ere used to analyze the inﬂuence of selected variables
occurrence of acute GVHD, conditioning regimen
with or without thiotepa for NST and with or with-
ut TBI for alloSCT], age, and underlying disease) on
he risk of HCMV infection; variables for the multi-
ariate models were selected with backward stepwise
limination, and signiﬁcance exceeding .05 was the
riterion for removal from the models.
ESULTS
ncidence and Treatment of HCMV Infection
Characteristics of HCMV infection in the 2 pa-
ient populations are reported in Table 2. After a
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4edian follow-up of 196 days (range, 102-390 days),
CMV active infection occurred in 17 (28.8%) of 59
ST patients, all of whom were allocated to the
CMV high-risk group. The median time to HCMV
ctive infection was 54 days (range, 16-245 days), with
cases of late infection, and the median peak number
f positive cells was 2 per 2  105 PBLs per slide
range, 1-39). Five (8%) of 59 patients developed
CMV viremia after a median time of 28 days (range,
3-58 days), with a median peak number of 2 (range,
-10) p72-positive human embryonic lung ﬁbroblast
HELF) per 2  105 PBLs inoculated. Overall, 14
82.3%) of 17 patients received ganciclovir preemptive
reatment, and in all cases active infection was suc-
essfully cleared after a median of 9 days of therapy
range, 7-21 days). No patient had recurrent infection
fter ganciclovir treatment. Three patients had self-
imiting HCMV active infection, with only 1 positive
est, not conﬁrmed at the subsequent control, and
hey therefore did not receive antiviral treatment. No
atient with HCMV disease was observed.
When looking at the matched cohort of hemato-
ogic patients treated with alloSCT, we observed an
CMV infection incidence rate of 85.4% (47/55),
ith 2 cases of self-limiting infection. On the whole,
4 cases of HCMV infection occurred in the high-risk
roup (recipient positive), whereas 1 case was ob-
erved in the low-risk group (donor and recipient both
egative) and 2 cases were observed in the intermedi-
te-risk group (donor positive, recipient negative). Ac-
ive HCMV infection occurred earlier (30 days; range,
3-64 days; P  .001), with no case of late infection.
he median antigenemia peak level was not different
rom that of NST patients (4; range, 1-55 pp65-
ositive PBLs), whereas 17 (30.1%) of 55 patients
eveloped viremia (median peak level, 4; range, 1-20
72-positive HELF) at a median time of 50 days
range, 27-150 days) after transplantation. In addition,
5 of 47 patients received ganciclovir therapy, with
irus clearance in all cases, after a longer median
reatment duration (20 days; range, 6-53 days; P 
able 2. Characteristics of HCMV Infection in the 2 Patient Populatio
Variable
ncidence of HCMV infection (%)
ime to HCMV infection, median (range) days after transplantat
eak antigenemia level, median (range)*
eak viremia level, median (range)†
uration of HCMV treatment, d, median (range)
ncidence of HCMV recurrent infection (%)
ncidence of HCMV disease
S indicates not signiﬁcant.
pp65-positive/2  105 PBLs.
pp72-positive human embryonic lung ﬁbroblast (HELF)/2  105001). After the ﬁrst course of ganciclovir treatment, C
260 patients (54.5%) had recurrent infection (6 had
elf-limiting and 24 had treatment-requiring infec-
ions). Preemptive therapy was effective in preventing
vert HCMV disease in all patients. As shown in
igure 1, the rate of HCMV infection was signiﬁ-
antly higher compared with that observed in patients
ith solid tumors after NST (85.4% versus 28.8%;
 .001; hazard ratio, 8.1; 95% conﬁdence interval,
.5-17.1).
VHD and HCMV Infection
GVHD data were available for all patients. In NST
atients, the distribution according to the degree of
cute GVHD expression was as follows: grade 0, 25
atients (42.5%); grade I, 14 patients (23.7%); grade II,
1 patients (18.6%); grade III, 6 patients (10%); and
rade IV, 3 patients (5%). The acute GVHD was usually
reated with prednisolone, reinstitution of Cs-A, or both.
he median duration of Cs-A administration was 106
ays (range, 57-510 days), with no signiﬁcant difference
ith respect to alloSCT patients.
In logistic regression analysis, the risk of HCMV
Type of Transplantation
P ValueNST AlloSCT
17/59 (28.8) 47/55 (85.4) <.001
54 (16-245) 30 (13-64) .001
2 (1-39) 4 (1-55) NS
2 (1-10) 4 (1-20) NS
9 (7-21) 20 (6-53) <.001
0 30 (54.5) <.001
0 0 NS
inoculated.
igure 1. Cumulative incidence of HCMV infection in patients
eceiving NST for solid tumors as compared with patients receiving
lloSCT for hematologic malignancies. HR indicates hazard ratio;ns
ionI, conﬁdence interval.
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Reduced and Delayed HCMV Infection after Allogeneic NST in Refractory Solid Tumors
Bnfection was signiﬁcantly associated with the occur-
ence of acute GVHD (P  .01; 95% conﬁdence
nterval, 1.96-135). Conversely, no signiﬁcant differ-
nces in the risk of HCMV infection were observed
etween the 2 nonmyeloablative regimens adminis-
ered (with or without thiotepa) or according to the
nderlying disease and age (50 and 50 years).
In alloSCT patients, acute GVHD distribution
as as follows: grade 0, 27 patients (49.1%); grade I,
7 patients (30.9%); grade II, 7 patients (12.7%);
rade III, 2 patients (3.6%); and grade IV, 2 patients
3.6%). No signiﬁcant correlation with HCMV infec-
ion was observed in alloSCT patients for acute
VHD, conditioning regimen (with or without TBI),
nderlying disease, or age (50 and 50 years).
ISCUSSION
Whether the incidence of HCMV infection is
educed after NST as compared with conventional
lloSCT has been addressed so far only in patients
ith hematologic diseases. Martino et al. [17] analyzed
1 nonmyeloablative and 123 myeloablative patients
eceiving allogeneic HCT from HLA identical sib-
ings and observed a signiﬁcant reduction in HCMV
nfection in the nonmyeloablative setting (21% versus
3% in the HCMV high-risk group; P  .03).
In a matched control study of 56 NST and 112
onventional alloSCT patients, Junghanss et al. [18]
bserved that the incidence of HCMV infection was
igniﬁcantly reduced during the ﬁrst 100 days in non-
yeloablated as compared with myeloablated patients
53% versus 78% in the HCMV high-risk group; P 
01) but that the overall 1-year incidence was similar;
hey concluded that the 2 groups of patients should
eceive the same surveillance. A greater risk of delayed
CMV infection in NST patients was also shown in
hat study. Other authors, focusing on HCMV and
ST in hematologic patients, reported a rate of
CMV infection that varied from 42% to 65%. [19-
2] These results, not always concordant, differ in
egard to the NST regimen administered and suggest
hat modulation of immunosuppression (with low doses
f TBI, Campath-1H, or T-cell depletion) plays a
ajor role in determining the risk of HCMV infec-
ion.
The incidence and outcome of HCMV infection
fter NST for solid tumors are largely unknown, be-
ause small series of patients have been reported so
ar. In our study, 59 patients, which represent the
argest cohort reported so far, were prospectively eval-
ated. Only approximately 30% of patients had an
ctive HCMV infection, and none had clinically overt
isease. The observed rate of active HCMV infection
s lower than that reported previously in this setting.
6,23,24] In addition, the general trend was toward a t
B&MTelayed appearance and a shorter treatment duration
f HCMV infection.
Because conventional alloSCT represents the stan-
ard model to which the NST approach is compared,
e investigated the incidence of HCMV infection in a
ohort of matched hematologic patients undergoing
lloSCT, and we observed a lower and delayed rate
nd a shorter treatment duration of HCMV infection
n NST patients. Even though this analysis was con-
ucted in 2 different cohorts of patients (hematologic
ersus solid tumors), it is worth noting the strength of
hese data, which may have clinical implications if they
re conﬁrmed in a prospective trial.
As expected, the risk of HCMV reactivation was
ssociated with acute GVHD in NST patients; con-
ersely, this correlation was not observed in alloSCT
atients. Although this lack of correlation was proba-
ly a bias due to the limited number of patients ana-
yzed, another hypothesis might be the more intensive
orticosteroid treatment (methylprednisolone 2-4 mg/
g/d in divided doses) administered in some cases of
lloSCT patients suspected of having early acute
VHD (grade 0). In our experience, the different
ollow-up in the 2 groups of patients (330 versus 910
ays) allowed an effective comparison for the HCMV
nfection during the ﬁrst 100 days and in the ﬁrst year
fter transplantation, but it rendered the risk of
CMV incidence/recurrence after the ﬁrst year not
valuable.
One possible explanation for such a difference in
CMV infection rates might be that our NST pa-
ients had not previously received intensive chemo-
herapy, and the conditioning regimens per se bear a
ow rate of infection and toxicity. In addition, it has
een shown [25,26] that NST is associated with a
ore rapid immune reconstitution as compared with
onventional alloSCT. This could entail a potentially
aster development of an effective immune response
gainst pathogens, thus reducing the overall infection
isk.
Moreover, the reduced transfusion requirement
n NST patients underlines the low risk of exposure to
ransfusion-transmitted HCMV infection with the
ST approach. Finally, an additional hypothesis,
hich needs conﬁrmation, is that patients harboring
olid malignancies would be less prone to HCMV
nfection as compared with hematologic patients be-
ause of the different immunologic impairment re-
ated to the underlying disease.
In conclusion, this study documents, regardless of
he mechanisms underlying the phenomenon, that pa-
ients with solid tumors undergoing NST have a re-
uced incidence and delayed appearance of active
CMV infection. Thus, in our experience, HCMV
nfection did not represent a major clinical problem in
his setting. Our results need conﬁrmation and, at
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4resent, do not justify a change in conventional
CMV surveillance after NST.
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